Emulsions of perfluoro compounds as solvents for nitric oxide (NO)

• US 5,869,539 A
• Filed: 04/17/1996
• Issued: 02/09/1999
• Est. Priority Date: 04/17/1996
• Status: Expired due to Fees

• Current Assignee: Texas A&M University System, Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Texas A&M University System, Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Garfield, R. E., Seitz, W. A., Balaban, A. T.
• Primary Examiner(s): Cintins, Marianne M.
• Assistant Examiner(s): Jones, Dwayne C.
• Application Number:
  US08/633,337
• Time in Patent Office: 1,028 Days
• Field of Search: 514/743, 514/746, 514/759, 514/832, 514/833, 424/718, 424/673
• US Class Current: 514/746
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention involves perfluoro compound emulsions including nitric oxide, their preparation and their use. These emulsions provide a new source of nitric oxide. Such nitric oxide-containing emulsions may be used for the administration of nitric oxide to individuals in need thereof. Individuals in need of nitric oxide administration can include those suffering from hypertension, preeclampsia and a number of other situations where an increased blood flow, for example, is desirable. In addition, given the long use of perfluoro compound emulsions as blood substitutes, the present invention provides a relatively safe mode for administering and distributing nitric oxide-without potential negative side effects such as toxicities due to drug metabolites.

Claims

1. A composition consisting essentially of a perfluoro compound emulsion with nitric oxide dissolved therein.

2. The composition of claim 1 where the perfluoro compound is further defined as being a perfluorinated hydrocarbon, a perfluorinated heterocyclic compound or a perfluorinated hydrocarbon amine.

3. The composition of claim 1 where the perfluoro compound is perfluorinated decalin, perfluorinated adamantane, perfluorinated tributylamine, perfluorinated tripropylamine, perfluorinated N-methyl-isoquinoline, perfluorinated N-(4-methylcyclohexyl)-piperidine), perfluorinated 2-n-butyl-tetrahydrofuran, perfluorooctyl-ethane, perfluorohexyl-ethane, 1,2-bis(perfluorobutyl)-ethene or 1,2-bis(perfluorohexyl)-ethene.

4. A method for preparing a nitric oxide source suitable for in vivo administration, the method comprising preparing or obtaining an emulsion consisting essentially of a perfluoro compound having nitric oxide dissolved in said emulsion.

5. A method for treating a mammal with nitric oxide comprising administering a composition consisting essentially of a perfluoro compound emulsion and nitric oxide in a therapeutically effective amount.

7. The method of claim 5 or 6 where the administering is parenteral, topical or intracavitary.

8. The method of claim 7 where the intracavitary administration is bronchial, cervical, uteral, vaginal, oral or anal.

9. The method of claim 7 where the parenteral administration is intravascular.

10. The method of claim 5 where nitric oxide treatment is to enhance blood perfusion to a particular site and the administration is proximate to that site.

6. A method for treating hypertension comprising administering a composition consisting essentially of a perfluoro compound emulsion with nitric oxide dissolved therein in a therapeutically effective amount.